PT  - JOURNAL ARTICLE
AU  - Yamana, Teresa K.
AU  - Galanti, Marta
AU  - Pei, Sen
AU  - Di Fusco, Manuela
AU  - Angulo, Frederick J.
AU  - Moran, Mary M.
AU  - Khan, Farid
AU  - Swerdlow, David L.
AU  - Shaman, Jeffrey
TI  - The impact of COVID-19 vaccination in the US: averted burden of SARS-COV-2-related cases, hospitalizations and deaths
AID  - 10.1101/2022.09.23.22280281
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.23.22280281
4099  - http://medrxiv.org/content/early/2022/09/25/2022.09.23.22280281.short
4100  - http://medrxiv.org/content/early/2022/09/25/2022.09.23.22280281.full
AB  - By August 1, 2022, the SARS-CoV-2 virus had caused over 90 million cases of COVID-19 and one million deaths in the United States. Since December 2020, SARS-CoV-2 vaccines have been a key component of US pandemic response; however, the impacts of vaccination are not easily quantified. Here, we use a dynamic county-scale metapopulation model to estimate the number of cases, hospitalizations, and deaths averted due to vaccination during the first six months of vaccine availability. We estimate that COVID-19 vaccination was associated with over 8 million fewer confirmed cases, over 120 thousand fewer deaths, and 700 thousand fewer hospitalizations during the first six months of the campaign.Competing Interest StatementTKY, MG, SP and JS are employees of Columbia University, which received funding from Pfizer in connection with the development of this study and of this manuscript. JS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI. MDF, FJA, MMM, and FK are employees of Pfizer and may hold stock or stock options. DS was employed at Pfizer at the time this work was conducted and he may own stock or stock options.Funding StatementThis study was sponsored by Pfizer Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:n/a no human dataI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableData will be held in a public repository at https://github.com/shaman-lab/